Purpose: To investigate the efficacy of permanent amniotic membrane transplantation (AMT) for the treatment of various ocular surface diseases.
Methods: The medical records of 62 eyes from 58 patients who had undergone permanent AMT were reviewed. The amniotic patches were grafted for the treatment of neurotrophic ulcers (n=15), inflammatory corneal ulcers (n=15), scleral ulcers (n=11), painful bullous keratopathy (n=8) and pterygium as an adjuvant to a conjunctival autograft (n=13). Cryo-preserved or freeze-dried amniotic membrane (AM) were used. The overall success rate, the interval to epithelialization, pain-subsiding time, and complications were evaluated. The pain relief and the full epithelialization interval in the bullous keratopathy patients given the cryo-preserved AM were compared with those given the freeze-dried AM.
Results: The success rate in the patients with neurotrophic ulcer, inflammatory corneal ulcer, scleral ulcer and bullous keratopathy were 93.3%, 66.7%, 92.9% and 100%, respectively. A conjunctival autograft with AMT showed a 100% success rate without recurrence. The time to re-epithelialization was 24.4+/-24.2, 20.4+/-5.8, and 16.9+/-7.0 days in patients with neurotrophic, inflammatory and scleral ulcers, respectively (p=0.431). The pain relief interval in the cryo-preserved and freeze-dried AM group was 17.7 and 23.3 days, and the re-epithelialization interval was 29 and 22 days, respectively, which was insignificant.
Conclusions: AMT has a high success in the treatment of neurotrophic, scleral ulcer, bullous keratopathy and pterygium with a low rate of complications but presented only partial success in the treatment of inflammatory corneal ulcers. The clinical efficacy of AMT was not related to the methods used to preserve the AM.
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1016/j.clae.2007.11.004 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
A first-in-human clinical study of an allogenic iPSC-derived corneal endothelial cell substitute transplantation for bullous keratopathy.
Cell Rep Med
January 2025
Department of Ophthalmology, Keio University School of Medicine, Shinjuku-ku 160-8582, Tokyo, Japan; Department of Clinical Regenerative Medicine, Fujita Medical Innovation Center, Fujita Health University, Ota-ku, Tokyo 144-0041, Japan. Electronic address:
A first-in-human investigator-initiated clinical study of a corneal endothelial cell substitute (CLS001) derived from a clinical-grade induced pluripotent stem cell (iPSC) line shows improvement of visual acuity and corneal stromal edema, with no adverse events for up to 1 year after surgery for the treatment of bullous keratopathy. While preclinical tests, including multiple whole-genome analysis and tumorigenicity tests adhering to the Food and Drug Administration (FDA) draft guidelines, are negative, an additional whole-genome analysis conducted on transplanted CLS001 cells reveals a de novo in-frame deletion of exon22 in the EP300 gene. No adverse events related to the mutation are observed.
View Article and Find Full Text PDFPredictors of cytomegalovirus corneal endotheliitis postcorneal transplantation.
Br J Ophthalmol
December 2024
Department of Ophthalmology, Kyoto Prefectural University of Medicine, Kyoto, Kyoto, Japan.
Purpose: This study was designed to investigate risk factors for the development of cytomegalovirus (CMV) corneal endotheliitis following corneal transplantation.
Methods: We retrospectively analysed 1225 corneal transplants for bullous keratopathy between 2011 and 2021. 31 cases who were administered the treatment of CMV corneal endotheliitis preoperatively were excluded, and 1194 cases were analysed for risk factors for the development of CMV corneal endotheliitis following corneal transplantation.
Current and emerging strategies for the manufacture, implantation, and clinical management of corneal tissue allografts.
Clin Exp Optom
December 2024
Centre for Vision and Eye Research, Queensland University of Technology, Brisbane, Queensland, Australia.
Article Synopsis
- Over the past 40 years, around 40,000 Australians have undergone corneal transplants, primarily due to conditions like keratoconus and Fuchs' dystrophy, with increasing demand due to an aging population.
- The global shortage of donor corneas is significant, with demand exceeding supply by 70 times, particularly in less-developed countries, prompting advancements in tissue banking and surgical techniques.
- New strategies like organ culture for donor corneas, bespoke surgical methods, and cell culture technologies are improving tissue storage, reducing transplant requirements, and enhancing patient care for corneal conditions.
Ripasudil's paradox: bullous keratopathy with honeycomb twist.
BMJ Case Rep
December 2024
Ophthalmology, All India Institute of Medical Sciences, Nagpur, India.
We present a case of a male patient in his mid-50s who presented with bullous keratopathy secondary to an anterior chamber intraocular lens, complicated by superimposed honeycomb keratopathy while on ripasudil 0.4%. The bullous keratopathy was characterised by generalised microcystic epithelial oedema, alongside more centrally located, variable-sized macrocystic epithelial oedema with a honeycomb appearance.
View Article and Find Full Text PDFFive Year Review of All Examined Corneal Tissue in a Tertiary Eye Care Center: Demographics and Surgical Indications.
J Epidemiol Glob Health
December 2024
Ophthalmology Department, King Saud University, Riyadh, Saudi Arabia.
Background: Corneal pathologies are among the most common reversible sight-threatening diseases globally. As such, corneal tissue transplantation (keratoplasty) techniques are evolving over time depending on the prevalence of different pathologies in each geographical area. We aim to provide a baseline information on the common keratoplasty procedures performed in our area in relation to prevalent corneal pathologies and to analyze common corneal surgical practice trends in our area.
View Article and Find Full Text PDFWant AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!